Replicating Gigantism to Maximize Height — The Science Behind EXTREME Supraphysiological HGH

shredded4summer

shredded4summer

Pretty Boy Chad
Joined
Jul 8, 2023
Posts
4,162
Reputation
6,855
Pathological Hypersecretion of Growth Hormone: The Endocrinology of Gigantism and Its Replicable Mechanisms

Gigantism and acromegaly are endocrine disorders arising from chronic hypersecretion of growth hormone (GH), typically due to a somatotroph adenoma of the anterior pituitary. The primary distinction between the two lies in the status of the epiphyseal growth plates: in gigantism, GH excess occurs before growth plate fusion, resulting in abnormal longitudinal skeletal growth and extreme height; in acromegaly, GH excess arises post-fusion, leading to soft tissue hypertrophy and appositional bone growth, without increased height.
In affected individuals, serum GH concentrations can exceed 100 ng/mL, compared to normal pulsatile peaks of ~3–5 ng/mL in healthy adolescents.

These elevated GH levels chronically stimulate hepatic production of insulin-like growth factor 1 (IGF-1), which acts in an endocrine, autocrine, and paracrine fashion on the epiphyseal growth plates, promoting chondrocyte proliferation, hypertrophy, and extracellular matrix production via activation of the PI3K-AKT-mTOR and JAK-STAT pathways. IGF-1 is the principal effector of somatic growth, mediating nearly all mitogenic and anabolic actions attributed to GH. This hormonal axis is self-amplifying: GH increases IGF-1, which in turn increases GH receptor density and potentiates sensitivity in growth-competent tissues.

Critically, there is no intrinsic saturation threshold for GH/IGF-1 signaling prior to growth plate fusion. As long as the cartilage of the growth plate remains unossified and active, increasing GH results in linearly increasing IGF-1 activity, with no evidence of physiological downregulation or feedback-induced resistance at the level of target tissues. The perceived “ceiling” to height in normal development is due not to a plateau in GH signaling but to the closure of growth plates via estrogen-induced epiphyseal fusion. Therefore, in gigantism, the absence of early estrogen exposure permits prolonged skeletal responsiveness to GH, often resulting in adult heights exceeding 210–220 cm.



To replicate the phenotype of gigantism pharmacologically, one must mimic both the endocrine environment and developmental timing. This involves three synergistic objectives:

  1. Supraphysiological GH administration: Exogenous recombinant human GH (rhGH), such as somatropin, must be administered in dosages that elevate circulating levels to those seen in adenoma-driven hypersecretion. Clinical acromegalics can produce over 50–100 IU of GH per day endogenously; therefore, experimental protocols targeting skeletal overgrowth should use 20–50 IU/day to mirror these levels. This drastically exceeds therapeutic replacement doses (~1–2 IU/day in GH-deficient individuals) and is necessary to induce pathological IGF-1 concentrations (>600–900 ng/mL).
  2. Estrogen suppression: Since epiphyseal fusion is governed primarily by estradiol (E2)—even in males via aromatization of testosterone—it is imperative to pharmacologically inhibit estrogen biosynthesis. Aromasin (Exemestane), a steroidal irreversible aromatase inhibitor, is the agent of choice due to its long half-life and high tissue penetration. By maintaining low systemic estrogen (<10 pg/mL), growth plates remain open and sensitive to the proliferative effects of GH/IGF-1. This mirrors the delayed fusion seen in prepubertal gigantism cases.
  3. Nutritional and anabolic support: While GH and IGF-1 provide the mitogenic signal, the morphological realization of height increase requires an abundance of substrates—calcium, phosphorus, vitamin D3, zinc, magnesium, and high-quality dietary protein and carbohydrated for matrix synthesis and mineralization. The structural demands imposed by forced hyperplasia of skeletal tissue are immense; deficiencies will attenuate growth and increase fracture risk.



In summary, there is no physiological "limit" to growth hormone-induced height gain, so long as the growth plates remain unfused and systemic IGF-1 remains elevated. Gigantism is not a unique genetic state, but a hormonal environment that can be partially recapitulated with pharmacology. The primary constraint is timing once fusion occurs, the window closes permanently. Thus, if one intervenes early enough with massive GH dosing and estrogen suppression, it is theoretically possible to engineer a controlled, synthetic form of gigantism, replicating the excessive height seen in pituitary disorders.



Example Synthetic Gigantism Stack


1. Human Growth Hormone (Somatropin)


  • Dose: 20–40 IU/day
  • Timing: Split into 2–3 subcutaneous injections daily (e.g., morning, midday, night) to mimic pulsatile secretion and minimize insulin resistance
  • Cycle Length: 6–18 months (or until epiphyseal fusion risk rises

2. Aromatase Inhibitor (Aromasin)


  • Dose: 12.5 mg every other day (EOD)
  • Monitoring: Estradiol target <15 pg/mL (via bloodwork every 4–6 weeks)
  • Form: Oral, take with fat-containing meal

3. Milk (Micronutrient & Caloric Base)


  • Amount: 2–3 liters/day
  • Macros (per liter): ~640 kcal / 32g protein / 48g carbs / 36g fat
  • Form: Preferably A2, grass-fed raw milk for maximal calcium, K2, and bioavailable fats


4. Red Meat (Protein & Micronutrients)


  • Amount: 600–800g/day (e.g., grass-fed beef, lamb)
  • Macros (per 100g): ~250 kcal / 26g protein / 20g fat
  • Micros: High in zinc, iron, B12, creatine, carnitine

5. Carbohydrates (Insulinogenic Support & Energy)


  • Target: 300–500g/day
  • Sources: White rice, honey, dates, fruit, bread
  • Timing: Emphasize post-injection to leverage GH-insulin synergy


Total Daily Intake (Example Target for 65–75kg adolescent)

  • Protein: 300g
  • Carbs: 400g
  • Fat: 150g
  • GH: 20–40 IU
  • Aromasin: 12.5mg EOD
Increase relative to height increase
 
Last edited:
  • JFL
  • +1
  • Hmm...
Reactions: Sonneillon, Enytraina, enlightful and 2 others
:feelsokman:
 
  • +1
Reactions: shredded4summer
Pathological Hypersecretion of Growth Hormone: The Endocrinology of Gigantism and Its Replicable Mechanisms

Gigantism and acromegaly are endocrine disorders arising from chronic hypersecretion of growth hormone (GH), typically due to a somatotroph adenoma of the anterior pituitary. The primary distinction between the two lies in the status of the epiphyseal growth plates: in gigantism, GH excess occurs before growth plate fusion, resulting in abnormal longitudinal skeletal growth and extreme height; in acromegaly, GH excess arises post-fusion, leading to soft tissue hypertrophy and appositional bone growth, without increased height.
In affected individuals, serum GH concentrations can exceed 100 ng/mL, compared to normal pulsatile peaks of ~3–5 ng/mL in healthy adolescents.

These elevated GH levels chronically stimulate hepatic production of insulin-like growth factor 1 (IGF-1), which acts in an endocrine, autocrine, and paracrine fashion on the epiphyseal growth plates, promoting chondrocyte proliferation, hypertrophy, and extracellular matrix production via activation of the PI3K-AKT-mTOR and JAK-STAT pathways. IGF-1 is the principal effector of somatic growth, mediating nearly all mitogenic and anabolic actions attributed to GH. This hormonal axis is self-amplifying: GH increases IGF-1, which in turn increases GH receptor density and potentiates sensitivity in growth-competent tissues.

Critically, there is no intrinsic saturation threshold for GH/IGF-1 signaling prior to growth plate fusion. As long as the cartilage of the growth plate remains unossified and active, increasing GH results in linearly increasing IGF-1 activity, with no evidence of physiological downregulation or feedback-induced resistance at the level of target tissues. The perceived “ceiling” to height in normal development is due not to a plateau in GH signaling but to the closure of growth plates via estrogen-induced epiphyseal fusion. Therefore, in gigantism, the absence of early estrogen exposure permits prolonged skeletal responsiveness to GH, often resulting in adult heights exceeding 210–220 cm.



To replicate the phenotype of gigantism pharmacologically, one must mimic both the endocrine environment and developmental timing. This involves three synergistic objectives:

  1. Supraphysiological GH administration: Exogenous recombinant human GH (rhGH), such as somatropin, must be administered in dosages that elevate circulating levels to those seen in adenoma-driven hypersecretion. Clinical acromegalics can produce over 50–100 IU of GH per day endogenously; therefore, experimental protocols targeting skeletal overgrowth should use 20–50 IU/day to mirror these levels. This drastically exceeds therapeutic replacement doses (~1–2 IU/day in GH-deficient individuals) and is necessary to induce pathological IGF-1 concentrations (>600–900 ng/mL).
  2. Estrogen suppression: Since epiphyseal fusion is governed primarily by estradiol (E2)—even in males via aromatization of testosterone—it is imperative to pharmacologically inhibit estrogen biosynthesis. Aromasin (Exemestane), a steroidal irreversible aromatase inhibitor, is the agent of choice due to its long half-life and high tissue penetration. By maintaining low systemic estrogen (<10 pg/mL), growth plates remain open and sensitive to the proliferative effects of GH/IGF-1. This mirrors the delayed fusion seen in prepubertal gigantism cases.
  3. Nutritional and anabolic support: While GH and IGF-1 provide the mitogenic signal, the morphological realization of height increase requires an abundance of substrates—calcium, phosphorus, vitamin D3, zinc, magnesium, and high-quality dietary protein and carbohydrated for matrix synthesis and mineralization. The structural demands imposed by forced hyperplasia of skeletal tissue are immense; deficiencies will attenuate growth and increase fracture risk.



In summary, there is no physiological "limit" to growth hormone-induced height gain, so long as the growth plates remain unfused and systemic IGF-1 remains elevated. Gigantism is not a unique genetic state, but a hormonal environment that can be partially recapitulated with pharmacology. The primary constraint is timing once fusion occurs, the window closes permanently. Thus, if one intervenes early enough with massive GH dosing and estrogen suppression, it is theoretically possible to engineer a controlled, synthetic form of gigantism, replicating the excessive height seen in pituitary disorders.



Example Synthetic Gigantism Stack (Experimental Use Only)


1. Human Growth Hormone (Somatropin)


  • Dose: 20–40 IU/day
  • Timing: Split into 2–3 subcutaneous injections daily (e.g., morning, midday, night) to mimic pulsatile secretion and minimize insulin resistance
  • Cycle Length: 6–18 months (or until epiphyseal fusion risk rises

2. Aromatase Inhibitor (Aromasin)


  • Dose: 12.5 mg every other day (EOD)
  • Monitoring: Estradiol target <15 pg/mL (via bloodwork every 4–6 weeks)
  • Form: Oral, take with fat-containing meal

3. Milk (Micronutrient & Caloric Base)


  • Amount: 2–3 liters/day
  • Macros (per liter): ~640 kcal / 32g protein / 48g carbs / 36g fat
  • Form: Preferably A2, grass-fed raw milk for maximal calcium, K2, and bioavailable fats


4. Red Meat (Protein & Micronutrients)


  • Amount: 600–800g/day (e.g., grass-fed beef, lamb)
  • Macros (per 100g): ~250 kcal / 26g protein / 20g fat
  • Micros: High in zinc, iron, B12, creatine, carnitine

5. Carbohydrates (Insulinogenic Support & Energy)


  • Target: 300–500g/day
  • Sources: White rice, honey, dates, fruit, oats, sourdough
  • Timing: Emphasize post-injection to leverage GH-insulin synergy


Total Daily Intake (Example Target for 65–75kg adolescent)

  • Protein: 300g
  • Carbs: 400g
  • Fat: 150g
  • GH: 20–40 IU
  • Aromasin: 12.5mg EOD
Increase relative to height increase
chatgpt ahh
 
  • +1
  • JFL
Reactions: Amphisbaena, shredded4summer and Sceptical
though 300 grams of protein might be excessive in my opinion
When growth velocity is artificially increased with extreme doses of HGH, protein requirements rise accordingly. You're accelerating bone elongation, muscle hypertrophy, and organ growth all of which require constant amino acid supply. The faster the body grows, the more raw material it needs. At extreme growth rates, 300g of protein isn’t excessive it’s proportional to the rate of tissue synthesis being forced pharmacologically.
 
  • Woah
Reactions: Sceptical
Not reading sadly
 
big hands big jaw.. thats what we all want
im talking about nose and ears. the cartilage there is especiallyt more sensitive to hgh so your gonna get a jew nose
 
  • JFL
Reactions: Lies oF nature
Beautiful thread, truly a masterpiece 🥹
 
  • +1
Reactions: shredded4summer
im talking about nose and ears. the cartilage there is especiallyt more sensitive to hgh so your gonna get a jew nose
you can just stop using if it grows, not that deep
 
  • Hmm...
Reactions: MyDreamIsToBe183CM
Pathological Hypersecretion of Growth Hormone: The Endocrinology of Gigantism and Its Replicable Mechanisms

Gigantism and acromegaly are endocrine disorders arising from chronic hypersecretion of growth hormone (GH), typically due to a somatotroph adenoma of the anterior pituitary. The primary distinction between the two lies in the status of the epiphyseal growth plates: in gigantism, GH excess occurs before growth plate fusion, resulting in abnormal longitudinal skeletal growth and extreme height; in acromegaly, GH excess arises post-fusion, leading to soft tissue hypertrophy and appositional bone growth, without increased height.
In affected individuals, serum GH concentrations can exceed 100 ng/mL, compared to normal pulsatile peaks of ~3–5 ng/mL in healthy adolescents.

These elevated GH levels chronically stimulate hepatic production of insulin-like growth factor 1 (IGF-1), which acts in an endocrine, autocrine, and paracrine fashion on the epiphyseal growth plates, promoting chondrocyte proliferation, hypertrophy, and extracellular matrix production via activation of the PI3K-AKT-mTOR and JAK-STAT pathways. IGF-1 is the principal effector of somatic growth, mediating nearly all mitogenic and anabolic actions attributed to GH. This hormonal axis is self-amplifying: GH increases IGF-1, which in turn increases GH receptor density and potentiates sensitivity in growth-competent tissues.

Critically, there is no intrinsic saturation threshold for GH/IGF-1 signaling prior to growth plate fusion. As long as the cartilage of the growth plate remains unossified and active, increasing GH results in linearly increasing IGF-1 activity, with no evidence of physiological downregulation or feedback-induced resistance at the level of target tissues. The perceived “ceiling” to height in normal development is due not to a plateau in GH signaling but to the closure of growth plates via estrogen-induced epiphyseal fusion. Therefore, in gigantism, the absence of early estrogen exposure permits prolonged skeletal responsiveness to GH, often resulting in adult heights exceeding 210–220 cm.



To replicate the phenotype of gigantism pharmacologically, one must mimic both the endocrine environment and developmental timing. This involves three synergistic objectives:

  1. Supraphysiological GH administration: Exogenous recombinant human GH (rhGH), such as somatropin, must be administered in dosages that elevate circulating levels to those seen in adenoma-driven hypersecretion. Clinical acromegalics can produce over 50–100 IU of GH per day endogenously; therefore, experimental protocols targeting skeletal overgrowth should use 20–50 IU/day to mirror these levels. This drastically exceeds therapeutic replacement doses (~1–2 IU/day in GH-deficient individuals) and is necessary to induce pathological IGF-1 concentrations (>600–900 ng/mL).
  2. Estrogen suppression: Since epiphyseal fusion is governed primarily by estradiol (E2)—even in males via aromatization of testosterone—it is imperative to pharmacologically inhibit estrogen biosynthesis. Aromasin (Exemestane), a steroidal irreversible aromatase inhibitor, is the agent of choice due to its long half-life and high tissue penetration. By maintaining low systemic estrogen (<10 pg/mL), growth plates remain open and sensitive to the proliferative effects of GH/IGF-1. This mirrors the delayed fusion seen in prepubertal gigantism cases.
  3. Nutritional and anabolic support: While GH and IGF-1 provide the mitogenic signal, the morphological realization of height increase requires an abundance of substrates—calcium, phosphorus, vitamin D3, zinc, magnesium, and high-quality dietary protein and carbohydrated for matrix synthesis and mineralization. The structural demands imposed by forced hyperplasia of skeletal tissue are immense; deficiencies will attenuate growth and increase fracture risk.



In summary, there is no physiological "limit" to growth hormone-induced height gain, so long as the growth plates remain unfused and systemic IGF-1 remains elevated. Gigantism is not a unique genetic state, but a hormonal environment that can be partially recapitulated with pharmacology. The primary constraint is timing once fusion occurs, the window closes permanently. Thus, if one intervenes early enough with massive GH dosing and estrogen suppression, it is theoretically possible to engineer a controlled, synthetic form of gigantism, replicating the excessive height seen in pituitary disorders.



Example Synthetic Gigantism Stack


1. Human Growth Hormone (Somatropin)


  • Dose: 20–40 IU/day
  • Timing: Split into 2–3 subcutaneous injections daily (e.g., morning, midday, night) to mimic pulsatile secretion and minimize insulin resistance
  • Cycle Length: 6–18 months (or until epiphyseal fusion risk rises

2. Aromatase Inhibitor (Aromasin)


  • Dose: 12.5 mg every other day (EOD)
  • Monitoring: Estradiol target <15 pg/mL (via bloodwork every 4–6 weeks)
  • Form: Oral, take with fat-containing meal

3. Milk (Micronutrient & Caloric Base)


  • Amount: 2–3 liters/day
  • Macros (per liter): ~640 kcal / 32g protein / 48g carbs / 36g fat
  • Form: Preferably A2, grass-fed raw milk for maximal calcium, K2, and bioavailable fats


4. Red Meat (Protein & Micronutrients)


  • Amount: 600–800g/day (e.g., grass-fed beef, lamb)
  • Macros (per 100g): ~250 kcal / 26g protein / 20g fat
  • Micros: High in zinc, iron, B12, creatine, carnitine

5. Carbohydrates (Insulinogenic Support & Energy)


  • Target: 300–500g/day
  • Sources: White rice, honey, dates, fruit, bread
  • Timing: Emphasize post-injection to leverage GH-insulin synergy


Total Daily Intake (Example Target for 65–75kg adolescent)

  • Protein: 300g
  • Carbs: 400g
  • Fat: 150g
  • GH: 20–40 IU
  • Aromasin: 12.5mg EOD
Increase relative to height increase
Nigger what the fuck is this
 
you can just stop using if it grows, not that deep
its irreversible

also you just wasted all your money for no reason, it would be better to just stick to 8 IU
 
  • +1
Reactions: niggacum492139
its irreversible

also you just wasted all your money for no reason, it would be better to just stick to 8 IU
mirrin low iq, id rather have gigantism then be a manlet. at least i can cut off hgh whenever i want
 
Last edited:
  • JFL
Reactions: MyDreamIsToBe183CM
mirrin low iq, id rather have gigantism then be a manlet. at least i can cut of hgh whenever i want
That’s not low iq nigger it’s called being reasonable

Bro 5’10 with good face is way better then 6’0 with ogre face
 
  • +1
Reactions: niggacum492139 and Deleted member 130915
  • +1
Reactions: MyDreamIsToBe183CM
You wont be ogre in 1 year
I was exaggerating on the ogre part, but it will be noticeable. Those mm of bone are everything

But also the risk reward ratio is bad, as you get older your chondrocyte are less active and decreased capacity, which also means HGH isn’t as effective
 
I was exaggerating on the ogre part, but it will be noticeable. Those mm of bone are everything

But also the risk reward ratio is bad, as you get older your chondrocyte are less active and decreased capacity, which also means HGH isn’t as effective
they still grow 2-6 inches during the last year of growth
 
  • Hmm...
Reactions: MyDreamIsToBe183CM

Users who are viewing this thread

Back
Top